Dihydroergocriptine

Products

Dihydroergocriptine is no longer registered in many countries. Cripar is out of commerce.

Effects

Dihydroergocriptine (ATC N04BC03) is dopaminergic and acts selectively on D2 receptors. It has no activity on serotoninergic or adrenergic receptors.

Indications

• Parkinson’s disease
• Early stages of Parkinson’s disease, as monotherapy or in combination with an L-dopa preparation.
• Interval treatment of migraine headaches.